Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Summit Therapeutics Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $35.3, while Summit Therapeutics Inc trades at $17.58 (market cap $13.98B). The key difference: GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| NVDL | SMMT | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $26.38 |
52-Week Low | $21.76 | $12.43 |
Market Cap | — | $13.98B |
Enterprise Value | — | $13.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.18, down 4.01% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF has delivered 12.66% year-to-date returns through June 8, 2026, outperforming the S&P 500. Recent stock splits on June 25-26, 2026, adjusted the share structure.
The leveraged ETF offers amplified exposure to Nvidia's AI-driven growth but faces risks from daily reset mechanics and tracking divergence. With Nvidia continuing to beat earnings estimates and maintain AI leadership, NVDL provides tactical upside potential, though volatility compression and leverage decay remain significant concerns for long-term holders.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
